ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of MXN 713.13 billion. The enterprise value is 711.07 billion.

Market Cap	713.13B
Enterprise Value	711.07B

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	May 8, 2025

Share Statistics

Current Share Class	146.55M
Shares Outstanding	n/a
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	-0.18%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.69M

Valuation Ratios

The trailing PE ratio is 26.57 and the forward PE ratio is 24.49.

PE Ratio	26.57
Forward PE	24.49
PS Ratio	6.95
PB Ratio	6.29
P/TBV Ratio	15.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.96, with an EV/FCF ratio of 22.18.

EV / Earnings	26.49
EV / Sales	7.21
EV / EBITDA	19.96
EV / EBIT	22.42
EV / FCF	22.18

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.15.

Current Ratio	3.41
Quick Ratio	2.06
Debt / Equity	0.15
Debt / EBITDA	0.46
Debt / FCF	0.54
Interest Coverage	139.28

Financial Efficiency

Return on equity (ROE) is 25.81% and return on invested capital (ROIC) is 16.54%.

Return on Equity (ROE)	25.81%
Return on Assets (ROA)	14.01%
Return on Invested Capital (ROIC)	16.54%
Return on Capital Employed (ROCE)	24.33%
Revenue Per Employee	10.28M
Profits Per Employee	2.69M
Employee Count	9,980
Asset Turnover	0.70
Inventory Turnover	2.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +56.09% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+56.09%
50-Day Moving Average	4,662.73
200-Day Moving Average	4,523.18
Relative Strength Index (RSI)	74.68
Average Volume (20 Days)	6

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.76

Income Statement

In the last 12 months, ResMed had revenue of MXN 102.63 billion and earned 26.84 billion in profits. Earnings per share was 182.11.

Revenue	102.63B
Gross Profit	60.93B
Operating Income	32.95B
Pretax Income	32.24B
Net Income	26.84B
EBITDA	36.07B
EBIT	32.95B
Earnings Per Share (EPS)	182.11

Full Income Statement

Balance Sheet

The company has 19.31 billion in cash and 17.16 billion in debt, giving a net cash position of 2.15 billion.

Cash & Cash Equivalents	19.31B
Total Debt	17.16B
Net Cash	2.15B
Net Cash Per Share	n/a
Equity (Book Value)	113.36B
Book Value Per Share	773.14
Working Capital	46.35B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 33.78 billion and capital expenditures -1.72 billion, giving a free cash flow of 32.06 billion.

Operating Cash Flow	33.78B
Capital Expenditures	-1.72B
Free Cash Flow	32.06B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.37%, with operating and profit margins of 32.10% and 26.15%.

Gross Margin	59.37%
Operating Margin	32.10%
Pretax Margin	31.41%
Profit Margin	26.15%
EBITDA Margin	35.14%
EBIT Margin	32.10%
FCF Margin	31.24%

Dividends & Yields

This stock pays an annual dividend of 41.98, which amounts to a dividend yield of 0.88%.

Dividend Per Share	41.98
Dividend Yield	0.88%
Dividend Growth (YoY)	27.54%
Years of Dividend Growth	1
Payout Ratio	23.14%
Buyback Yield	0.07%
Shareholder Yield	0.96%
Earnings Yield	3.76%
FCF Yield	4.50%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.61.

Altman Z-Score	12.61
Piotroski F-Score	n/a